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Abstract
Hepatitis C virus (HCV) NS5A protein transcriptionally modulates a number of cellular genes. Since there is no evidence of binding of
NS5A protein to DNA, it is likely to exert its activity in concert with cellular factor(s). In this study, we have identified a specific interaction
of HCV NS5A with homeodomain protein PTX1 of human origin by a yeast two-hybrid interacting cloning system. The authenticity of this
interaction was verified by mammalian two-hybrid assay, in vivo co-immunoprecipitation analysis, and from a colocalization study.
Recently, murine PTX1 (mPTX1) has been shown to repress virus-induced murine interferonA4 promoter activity. Interferon- alone or
together with ribavirin is the only available therapy for HCV-infected patients. Therefore, we examined whether coexpression of NS5A and
human PTX1 (hPTX1) proteins modulate human IFN- promoter activity. An in vitro reporter assay by transfection of HepG2 cells with
NS5A suggested an activation of IFN- promoter to 20-fold upon Newcastle disease virus (NDV) infection. Under similar experimental
conditions, hPTX1-activated IFN- prompter to sevenfold, unlike mPTX1. However, cotransfection of NS5A and hPTX1 displayed a
lower interferon promoter activity, probably for physical association between these two proteins. Subsequent study demonstrated that
activation of IFN promoter by NS5A is associated with an increased expression of IRF-3. Further analysis revealed that ectopic expression
of NS5A in HepG2 cells enhances endogenous IFN- secretion and MxA expression upon induction with NDV. However, exogenous
expression of hPTX1 did not significantly alter NS5A-mediated function in the stable transfectants. Taken together, these results suggested
that the level of endogenous hPTX1 is not sufficient to block the function of NS5A for augmentation of virus-mediated IFN activity in
HepG2 cells.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
HCV is an important cause of morbidity and mortality
worldwide, causing a spectrum of liver disease ranging from
an asymptomatic carrier state to end-stage liver disease. The
most important feature of HCV infection is the development of
chronic hepatitis in a significant number of infected individuals
and the potential for disease progression to hepatocellular car-
cinoma (Di Bisceglie, 1997; Hayashi et al., 1999; Jeffers,
2000; Saito et al., 1990), one of the commonest internal ma-
lignancies of mankind. HCV multiplication is sustained
throughout the course of infection and during development of
hepatocellular cancer (Kato et al., 1993; Nousbaum et al.,
1995). Several HCV proteins have been implicated for virus-
mediated pathogenesis (Reed and Rice, 2000). HCV genome
contains a linear, positive-strand RNA molecule of 9500
nucleotides (Choo et al., 1989; Kaito et al., 1994). RNA tran-
scripts from cloned HCV cDNA can initiate infection leading
to hepatitis by direct intrahepatic injection into chimpanzees
(Kolykhalov et al., 1997; Yanagi et al., 1997). The HCV
genome encodes a single polyprotein precursor of 3000
amino acids (Choo et al., 1989), which is cleaved by both host
and viral proteases (Grakoui et al., 1993; Hijikata et al., 1991)
to generate at least 10 individual proteins.
The NS5 region of the polyprotein is composed of two
major proteins, NS5A (p56) and NS5B (p65), which are gen-
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erated as mature products by the action of the NS3 protease in
conjunction with NS4A. NS5A exists as two phosphoproteins
p56 and p58, which are phosphorylated at serine residues after
the mature NS5A protein is released from the polyprotein
(Kaneko et al., 1994; Tanji et al., 1995). Although phosphor-
ylation of HCV NS5A occurs predominantly on serine, a low
level of phosphorylation on threonine residues was also ob-
served (Reed et al., 1997). Sequence comparison of the regions
surrounding the sites of phosphorylation indicates an ex-
tremely high level of conservation between different strains of
the virus but the biological significance of phosphorylation is
still unclear. Results from replicon system supports that NS5A
is an important component in HCV replication (Blight et al.,
2000). NS5A protein has been implicated in HCV antiviral
resistance (Tan and Katze, 2001). The sensitivity to IFN was
correlated with mutations within the discrete region of NS5A
and named IFN sensitivity determining region (ISDR) (Eno-
moto et al., 1995, 1996; Schiappa et al., 2002). However, the
selective pressures evoked on HCV quasispecies during IFN
therapy appear to vary among different patients; ISDR locus
per se does not function in a manner consistent with a major
role in mediating IFN resistance (Polyak et al., 1998).
HCV NS5A protein is likely to play an important role in
virus–host interaction. NS5A modulates a number of cell-
cycle regulatory genes (Ghosh et al., 1999, 2000a; Majum-
der et al., 2001) and promotes murine fibroblasts to a trans-
formed phenotype (Ghosh et al., 1999; Gale et al., 1999).
Since NS5A does not bind to the DNA directly, it probably
exerts its effect through other protein(s). NS5A downregu-
lates the p21 gene by sequestering p53 in the cytoplasm
(Majumder et al., 2001) and exerts antiapoptotic activity in
mammalian cells (Gale et al., 1999; Ghosh et al., 2000b), as
well as in transgenic mice (Majumder et al., 2002). Here, we
demonstrated that HCV NS5A protein physically associates
with homeodomain transcription factor PTX1. Since mouse
PTX1 (mPTX1) represses virus-induced IFNA4 promoter
(Lopez et al., 2000), we investigated the role of NS5A for
modulation of IFN activity.
Results
Identification of NS5A interacting proteins by yeast two-
hybrid screening
We undertook a search for host cellular proteins that
interact with NS5A using yeast two-hybrid interaction clon-
ing. HF7c yeast cells expressing NS5A were transformed
with plasmid DNAs from a cDNA library. The candidate-
interacting colonies were selected on the basis of their
ability to grow in appropriate selection medium and turn on
the LacZ reporter gene (Ghosh et al., 2000a). Thirty clones
were grown in histidine-deficient selective medium and
exhibited -galactosidase activity. Plasmid DNA was iso-
lated from 17 clones and re-transformed into HF7c yeast
cells expressing Gal4-NS5A gene for positive interaction.
All clones exhibited growth in selective medium and -ga-
lactosidase activity following retransformation. Upon fur-
ther testing of these clones for interaction with a battery of
heterologous baits in yeast, six clones were found to spe-
cifically interact with pGBT9-5A and not with other heter-
ologous protein baits. These clones were sequenced and
analyzed using the BLAST program. Sequence analysis
revealed that two isolates represent an independent full-
length cDNA clone with perfect homology to a human
homeodomain protein PTX1 (GenBank Accession No.
NM_002653).
Association of NS5A with human PTX1 in mammalian
cells
The mammalian version of the conventional two-hybrid
assay was used to ascertain whether NS5A associates with
PTX1. For this purpose, we constructed mammalian expres-
sion plasmid vectors encoding a VP16-5A fusion protein
and Gal4 DNA-binding domain protein fused to PTX1
(Gal4-PTX1). The mammalian two-hybrid assay was per-
formed by transfecting HepG2 cells with a Gal4-responsive
reporter gene (gE1bCAT) and pairwise combinations of the
appropriate expression vectors. Reporter gene expression
was determined by measuring CAT activity in cell lysates
from each transfected culture. A significant increase in CAT
activity was observed following coexpression of VP16-5A
and Gal4-PTX1 hybrids (Fig. 1). However, CAT activity
was not enhanced by coexpression of the VP16-5A and
Gal4 vector or Gal4-PTX1 and VP16 Flag vector as a
negative control (data not shown).
NS5A-hPTX1 form complex in vivo
A co-immunoprecipitation experiment was performed
with lysates of HepG2 cells cotransfected with NS5A and
CMVFlag-PTX1 to verify the ability of NS5A for associa-
tion with PTX1 (Fig. 2). Cell lysates were incubated with
pooled normal mouse sera as a negative control (Lane 1) or
monoclonal antibody to Flag for immunoprecipitation
(Lanes 2 and 3). The immunoprecipitates immobilized on
protein A–Sepharose beads were separated by SDS–PAGE
and blotted onto nitrocellulose membrane. Coprecipitation
of NS5A with PTX1 was observed from the reactivity with
specific antibody and the size of the NS5A protein. Cell
lysates were also analyzed by Western blot and the presence
of NS5A protein band was detected with specific antibody
(Lanes 4 and 5). The protein bands with slower mobility
(85 kDa) detected in co-immunoprecipitated samples
(Lanes 2 and 3) could not be definitely identified. The blot
was stripped and, when reprobed with a monoclonal anti-
body to Flag, displayed the hPTX1 protein band (bottom).
Therefore, specific association of NS5A and hPTX1 was
observed using a mammalian two-hybrid assay and co-
immunoprecipitation analysis.
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NS5A colocalizes with hPTX1
We transfected cells with CMVFlag-PTX1 to examine
its localization. Indirect immunofluorescence was per-
formed using a monoclonal antibody to Flag and a predom-
inant cytoplasmic localization of hPTX1 was observed (Fig.
3A). Next, cells were cotransfected with CMV-NS5A and
CMVFlag-PTX1, and 48 h posttransfection cells were sub-
jected to indirect immunofluorescence together with a
mouse monoclonal antibody to Flag (Fig. 3B) and a rabbit
antiserum to NS5A (Fig. 3C). Cytoplasmic localization of
both hPTX1 and NS5A was observed. Confocal microscopy
suggested colocalization of PTX1 and NS5A proteins pre-
dominantly in the cytoplasm of the cells (Fig. 3D), while
control antibodies did not produce any detectable fluores-
cence (data not shown).
Mapping of hPTX1-binding domain in NS5A
To identify the region of NS5A responsible for binding
with hPTX1, a mammalian two-hybrid assay was performed
using Gal4-PTX1, VP16-5A, and its deletion mutants (Ma-
jumder et al., 2001). A significant increase (fivefold) in
CAT activity was observed when full-length NS5A, VP16-
5A1-332, and VP16-5A1-220 were cotransfected with Gal4-
Fig. 1. Interaction of NS5A with PTX1 in mammalian two-hybrid system.
HepG2 cells were transfected with 1 g gE1b-CAT reporter gene, 1 g of
VP16-5A, and increasing doses of (1, 2, and 3 g, denoted by , , and
) of Gal4-PTX1. CAT assay was performed 48 h posttransfection.
Amount of DNA was kept constant in each transfection by adding the
empty vector DNA. PTX1-5A hybrid displayed a high level of CAT
activity as compared to Gal4-PTX1 or NS5A alone. Chloramphenicol
acetylated (1%) was arbitrarily assigned to the vector control.
Fig. 2. Coimmunoprecipitation of hPTX1 with HCV NS5A. HepG2 cells were
cotransfected with NS5A and CMVFlag-PTX1, and cells were lysed after 48 h
of transfection. Cell lysates were immunoprecipitated with pooled normal
mouse sera as a negative control (Lane 1) or with a monoclonal antibody to
Flag in duplicate experiments (Lanes 2 and 3). Immunoprecipitates were
separated by SDS–7.5% PAGE, blotted onto nitrocellulose, and probed with a
rabbit antibody to NS5A. A secondary antibody conjugate (anti-rabbit IgG/
horseradish peroxidase, Amersham) was used for detection of the peroxidase
signal by chemiluminescence (ECL). The molecular weight of the NS5A band
(58 kDa) was ascertained from the migration of standard protein molecular
weight markers (Life Technologies). The positions of NS5A and Ig heavy
chain are shown. Cell lysates were also analyzed by SDS–PAGE and the
presence of NS5A protein band was detected using specific antibody (Lanes 4
and 5). The blot was reprobed with Flag monoclonal antibody for detection of
hPTX1 (bottom).
Fig. 3. Colocalization of hPTX1 and NS5A in HepG2 cells. Immunoflu-
orescent staining using Flag epitope specific antibody exhibited cytoplas-
mic localization of hPTX1 in CMVFlag-PTX1-transfected HepG2 cells
(A). Cells cotransfected with NS5A and PTX1 were stained with a mono-
clonal antibody to Flag for PTX1 (B) and a rabbit antibody to NS5A (C).
Fluorescence images of B and C when superimposed digitally for fine
comparison displayed colocalization of PTX1 and NS5A (D).
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PTX1, but not with VP16-5A1-133 (Fig. 4). However, CAT
activity was not altered following coexpression of NS5A
deletion mutants and Gal4 empty vector as a negative con-
trol. Results from this assay indicated that PTX1-interacting
domain is localized between amino acid positions 133 and
220 of NS5A. These findings suggested association of
PTX1 occurs through a specific region of NS5A, although
the precise sequences responsible for this interaction re-
mains to be identified.
NS5A and hPTX1 enhances human interferon promoter
activity
We next investigated the role of hPTX1 and HCV NS5A
on human IFN- promoter. An in vitro reporter assay was
performed by cotransfecting HepG2 cells with human
IFNA4 promoter linked to luciferase reporter gene, empty
vector, CMV-NS5A, and/or CMVFlag-PTX1. Cells were
infected with NDV (m.o.i. 5) after 16 h of transfection or
left uninfected and luciferase activity was measured 24 h
postinfection. Results suggested that expression of NS5A or
hPTX1 activates virus-induced human IFNA4 promoter in
HepG2 cells, while significant change was not observed in
uninfected cells (Fig. 5). However, coexpression of NS5A
and hPTX1 reduced human IFNA4 promoter activity as
compared to NS5A or PTX1 alone, suggesting an associa-
tion of these two proteins may prevent promoter activation.
Similar results were also obtained when cells were trans-
fected with IFNA14 promoter (data not shown). Results
from these experiments suggested that the presence of
NS5A or hPTX1 activates IFNA4 promoter upon induction
with NDV.
NS5A enhances IRF-3 expression
The IRF-3 and IRF-7 have been identified as direct
transducers of virus-mediated signaling and play a critical
role in the induction of Type I IFN genes (Sen, 2001). IRF-3
is expressed widely in cells and demonstrated a unique
response to virus infection. Unlike IRF-3, IRF-7 is not
expressed constitutively in cells and induced by IFN or
virus infection. To further understand how NS5A regulates
the IFNA4 promoter activity, we examined the expression
level of IRF-3 and IRF-7. HepG2-neo or HepG2-NS5A
cells were transiently transfected with hPTX1. Cells were
infected with NDV (m.o.i. 5) and cell lysates were collected
24 h postinfection. Western blot analysis was performed
using specific antibody to IRF-3 (Fig. 6). Our results sug-
Fig. 4. Mapping of the hPTX1-binding domain in NS5A. Cells were cotransfected with gE1b-CAT reporter gene and pairwise combination of Gal4-PTX1
and various deletion mutants of NS5A in VPFlag vector. CAT assay was performed 48 h posttransfection. A significant increase of CAT activity (fivefold)
over basal level is indicated by . Position of amino acids in the deletion mutants of NS5A is indicated by horizontal bars.
Fig. 5. Activation of virus-induced human IFNA4 promoter by NS5A and
hPTX1. Cells were cotransfected with human IFNA4-luc reporter gene and
the indicated expression constructs. The total amount of DNA was kept
constant by addition of empty vector in each transfection. Cells were
infected with NDV as described under Materials and Methods and cell
extracts were prepared for luciferase assay. In each set of experiments,
triplicate transfections were performed and basal value was arbitrarily set
at 1.
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gested a significant increase of IRF-3 expression (20-fold)
in HepG2-NS5A cells (Lane 3) as compared to control
HepG2-neo cells. HepG2-NS5A cells transiently trans-
fected with hPTX1 also displayed an increased level of
IRF-3 expression (Lane 4). Unlike the results of IFNA4
promoter regulation in an in vitro transient transfection
assay, the lack of IRF-3 inhibition by coexpression of
NS5A-hPTX1 may arise from the difference between the
expression level of NS5A and hPTX1 in HepG2-NS5A
stable transfectants. On the other hand, HepG2-neo cells
alone (Lane 1) or when transfected with hPTX1 (Lane 2)
did not display a detectable IRF-3 expression upon NDV
infection. Therefore, the mechanism of virus-induced
hPTX1-mediated IFNA4 promoter activation may follow a
different mechanism and remains to be elucidated. We also
examined the level of IRF-7 under similar experimental
conditions and did not observe a detectable expression. This
could be due to no or very little expression of IRF-7 in
human liver cells (Au et al., 1998) and may explain the
relative weakness of hepatocytes for IFN stimulation (Ke-
skinen et al., 1999).
NDV-mediated IFN- secretion is enhanced by NS5A
To determine the role of NS5A in the induction of
NDV-mediated IFN expression, HepG2 cell-culture me-
dium was examined for secretion of IFN- by ELISA (R&D
Systems, MN). HepG2-neo or HepG2-NS5A/hPTX1 cell-
culture supernatant was collected 48 h postinfection with
NDV. A detectable amount of human IFN- (sensitivity
12.5 pg/ml) in vector-transfected HepG2 cell supernatant
was not observed (Table 1). This may be due to intrinsic
property of hepatoma cells with poor ability to produce and
respond to type I IFNs, which may contribute to their
inability to efficiently resist viral infections (Keskinen et al.,
1999). Interestingly, cells transfected with hPTX1, although
displayed sevenfold increase in IFNA4 promoter activity,
did not induce a detectable amount of IFN- secretion in the
culture medium. This could be due to higher sensitivity of
the luciferase activity in comparison to ELISA-based IFN
assay. On the other hand, ectopic expression of NS5A in
HepG2 cells significantly enhanced NDV-mediated stimu-
lation of IFN- (208  7 pg/ml) and corroborated with a
significant increase in IFNA4 promoter activation (20-
fold). However, exogenous expression of hPTX1 in HepG2-
NS5A cells slightly decreased virus-mediated IFN- secre-
tion (165  6 pg/ml). Together, these results suggested that
the level of endogenous hPTX1 is not sufficient to block the
function of NS5A for augmentation of virus-induced IFN
activity in HepG2 cells.
IFN- is produced by most cells in response to viral
infection. The binding of IFN- to its receptor mediates a
signal cascade that results in the transcriptional induction of
IFN-induced genes. Although most of these genes are of
unknown function, several have demonstrable antiviral ac-
tivity. MxA gene is activated as a secondary response to
NDV-induced interferon (Bazzigher et al., 1992). MxA is a
guanosine triphosphatase and inhibits the replication of
RNA viruses. Since we could not detect IFN- secretion in
NDV-induced HepG2 cell-culture medium, the cell-associ-
ated downstream molecule MxA of IFN pathway was ex-
amined. Upon NDV induction, an almost undetectable level
of MxA was observed in HepG2-neo control cells by West-
ern blot analysis using a specific antibody (Fig. 7). On the
other hand, HepG2-NS5A cells displayed a significant level
of MxA expression upon NDV induction and exogenous
expression of hPTX1 did not alter MxA expression in
HepG2-NS5A cells. Protein concentration was normalized
by reprobing the blot with an antibody to actin. Basal-level
Fig. 6. HCV NS5A protein enhances IRF-3 expression in HepG2 cells
upon NDV induction. HepG2-neo control cells (Lane 1), transfected with
hPTX1 (Lane 2), and HepG2-NS5A cells (Lane 3) or HepG2-NS5A cells
transfected with hPTX1 (Lane 4), were induced with NDV for 24 h. Cell
lysates were analyzed by Western blot using a polyclonal antibody to
IRF-3 (Santa Cruz). The molecular weight of IRF-3 band was ascertained
as 50 kDa from the migration of standard protein molecular weight
markers (Life Technologies). The blot was reprobed with antibody to actin
for comparison of protein level.
Table 1
NDV-Mediated Induction of IFN- in HepG2 Cells Expressing HCV
NS5A
Cells IFN- production (pg/ml)a
NDV NDV
HepG2-neo 12.5 12.5
HepG2-neo  hPTX1 12.5 12.5
HepG2-NS5A 12.5 208  7
HepG2-NS5A  hPTX1 12.5 165  6
a The value  12.5 pg/ml denotes the lower limit of detection of IFN-
level. Results are presented from mean of three independent experiments.
Fig. 7. HCV NS5A protein enhances MxA expression in HepG2 cells upon
NDV induction. HepG2-neo control cells (Lane 1) transfected with hPTX1
(Lane 2), and HepG2-NS5A cells (Lane 3) transfected with hPTX1 (Lane
4), were induced with NDV for 24 h. Cell lysates were analyzed by
Western blot using monoclonal antibody to MxA. The molecular weight of
MxA band was ascertained as 76 kDa from the migration of standard
protein molecular weight markers (Life Technologies).
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MxA was not detected in uninfected HepG2-neo or HepG2-
NS5A cells (not shown in figure). This result corroborates
with our findings (Table 1) that endogenous IFN- produc-
tion is enhanced in HepG2 cells expressing NS5A.
Discussion
Our observations suggest that HCV NS5A protein from
genotype 1a physically associates with homeodomain pro-
tein PTX1 and colocalizes in the cytoplasm of HepG2 cells.
Functional data indicate that NS5A or hPTX1 alone en-
hances NDV-induced IFNA4 promoter activity in an in
vitro transient transfection assay. However, coexpression of
NS5A and hPTX1 proteins reduces IFNA4 promoter activ-
ity close to basal level probably for physical association
between these two interacting proteins. PTX1 gene is ex-
pressed during embryogenesis, in adult tissues, and in dif-
ferent cell lines (Lopez et al., 2000; Tremblay et al., 2000).
Homeodomain transcription factors function by positively
or negatively regulating spatial and temporal patterns of
gene expression. The activity of PTX1 as a positive tran-
scriptional regulator is synergized by cell-restricted tran-
scription factors (Poulin et al., 1997; Szeto et al., 1996;
Tremblay et al., 1999; Tremblay and Drouin, 1999). Oct-1,
a homeodomain transcription factor, activates different pro-
moters and is also involved in repression of the hPit1 gene
(Delhase et al., 1996). Human homolog of mPTX1 represses
virus-induced murine IFNA4 promoter activity by binding
to promoter sequences (Lopez et al., 2000). Sequence com-
parison suggested that human and mouse IFNA4 promoters
are different. Furthermore, the sequences (DNRE) where
mPTX1 binds to the murine IFNA4 promoter are not
present in human IFNA4 promoter. Therefore, these two
promoters may be regulated by distinct mechanisms. It is
possible that hPTX1 modulates human IFNA4 promoter by
DNA-independent protein–protein interaction through other
cellular factor(s). Our results suggest that HCV NS5A en-
hances IRF-3 expression upon NDV infection; however,
IRF-7 expression could not be observed. At present, we do
not know whether elevation of IRF-3 by NS5A upon NDV
induction is due to the altered mRNA induction or protein
stability. It is possible that NS5A may disrupt a cellular
proteosome pathway to enhance IRF-3 stability (Servant et
al., 2001). Thus, the mechanism of IRF-3 elevation by
NS5A remains to be investigated. Both IRF-3 and IRF-7 are
regulated in part by virus induction; however, these tran-
scription factors impart complementary rather than redun-
dant functional roles in cytokine gene activation (Lin et al.,
2000a). In fact, human IRF-7 is expressed effectively only
in lymphoid tissues, peripheral blood mononuclear cells,
and some cell lines of lymphoid origin, and its transcription
can be further stimulated by treatment with IFN (Au et al.,
1998). However, none or very little expression of IRF-7
could be detected in established cell lines of fibroblast or
epithelial origin including liver. This could account for
undetectable IRF-7 expression in NDV-infected HepG2
transfectants.
At present, the only approved therapy for chronic HCV
infection is IFN- with or without ribavirin (Hoofnagle and
Di Bisceglie, 1997; McHutchison et al., 1998; Moradpour
and Blum, 1999). The sustained antiviral response rate of
IFN- monotherapy is low (30%) and combination ther-
apy with ribavirin is higher (50%) in treated patients
(Poynard et al., 1996; Alter and Seeff, 2000; Jaeckel et al.,
2001; Rosen et al., 2002). The functional role of HCV
proteins in the regulation of interferon signaling pathways is
important to understand. HCV NS5A has been implicated
for interference of IFN-mediated antiviral activity (Tan and
Katze, 2001). However, a hepatoma cell line (Huh7)
adapted HCV replicons from genotype 1b using IRES from
EMCV displayed high susceptibility to IFN- treatment,
independent of a number of mutations in NS5A (Barten-
schlager, 2002; Blight et al., 2000; Guo et al., 2001). Inhi-
bition of the virus-replicative cycles from HCV 1a and 1b
by IFN- in hepatocytes has also been suggested (Chung et
al., 2001; Castet et al., 2002). Thus, the role of mutations in
NS5A protein during clinical response to IFN- therapy and
the in vitro effects of NS5A on the IFN system are not yet
well understood. Recently, IRES from EMCV has been
suggested to be sensitive to IFN, while HCV IRES is resis-
tant (Koev et al., 2002). This might prevent the early de-
fense response which may allow the completion of the first
stages of virus life cycle, as a result virus could replicate in
cells. Subsequently, viral proteins in concert with host pro-
teins may trigger the signal transduction pathway in deter-
mining resistance or sensitivity to IFN.
Although we have examined the virus-induced activation
of IFNA4 promoter among 14 subtypes of IFN- promot-
ers, HepG2 cells expressing NS5A displayed a significant
level of endogenous IFN- production and MxA expression
as a secondary response to IFN in cells. In contrast, endog-
enous IFN- secretion or induction of MxA could not be
detected after NDV infection of vector-transfected HepG2
cells. This result is in agreement with Keskinen et al.,
(1999), where they also observed that HepG2 cells infected
with influenza A or Sendai virus did not produce a detect-
able level of IFN-. We do not have conclusive evidence as
to whether HCV stimulates endogenous IFN- production
for activation of innate antiviral host responses (Castelruiz
et al., 1999; Jakschies et al., 1994). However, expression of
several IFN-induced genes, MxA, IP-10, IFI-56K, and p44,
in the liver of HCV-infected patients was found to be
significantly enhanced (Patzwahl et al., 2001). IFN-induced
genes are also stimulated during HCV RNA replication
within the liver of acutely infected chimpanzees (Bigger et
al., 2001). These results indicate that HCV may be an
activator of IFN-inducible genes. While our manuscript was
in preparation, Frederucksen et al., (2002) reported that
continuous expression of nonstructural genes from HCV 1b
replicon enhances IFN- production upon Sendai virus in-
fection in Huh7 cells. However, the contribution of specific
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nonstructural proteins were not examined. To our knowl-
edge, this is the first report on activation of human IFNA4
promoter and IFN- production upon virus induction in
hepatocytes expressing NS5A. IFNs are important regula-
tors of genes encoding for proteins involved in the signal
transduction of IFN and other cytokines. IFN-/ is pro-
duced by virus-infected host cells and constitutes the pri-
mary response against infection. Both IFN- and IFN-/
follow similar downstream pathways for antiviral activity.
HCV may induce interferon production upon infection of
target cells. However, the downstream pathways for IFN-
mediated anti-HCV activity in human hepatocytes remains
to be elucidated. In fact, 20% of the HCV-infected pa-
tients naturally clear virus infection, although the mecha-
nism of this virus clearance is not well understood. En-
hancement of IFN- along with other immunological
mechanisms may play a significant role in virus clearance in
these individuals. However, our observations should not be
interpreted to mean that activation of IFN- production by
HCV NS5A is the only mechanism for viral clearance or
sensitivity to IFN- therapy. A recent finding suggests that
IFN- can block HCV replication in primary human hepa-
tocyte culture (Castet et al., 2002). These observations and
clinical outcome of IFN- trial (Manns et al., 2001) under-
score critical investigations in elucidating the mechanism of
both responsiveness and resistance of HCV and the altered
nature of immune responses during IFN- treatment.
Materials and Methods
Yeast two-hybrid screening
In search of an interacting host protein with HCV NS5A,
a yeast two-hybrid screening was carried out in which the
entire cDNA-coding region of HCV NS5A (genotype 1a, H
strain) was fused in-frame with the Gal4 DNA-binding
domain into the pGBT9 plasmid vector (Clontech) as a bait
for screening a cDNA library (Ghosh et al., 2000a). Auton-
omous activation of the reporter gene was not observed by
NS5A. The screening procedure was previously described
(Ghosh et al., 2000a). At least 2.5  106 colonies were
screened and colonies were selected on agar plates lacking
histidine, tryptophan, and leucine over a 7-day period. Pos-
itive yeast transformants were picked up and replated for
-galactosidase assay by colony-lift filter procedure. A pos-
itive interaction was determined by the appearance of blue
colonies. The -gal positive colonies were grown on a
selective medium for plasmid DNA isolation. Isolated plas-
mids were transformed into Escherichia coli KC8 strain and
selected for the activation domain plasmids on M9-leu
agar plates. The potential NS5A interacting cDNA inserts
were retransformed into HF7c yeast strain bearing
pGBT9-5A fusion gene and were grown on an appropriate
selective medium for -gal assay. Positive interacting
cDNA clones were analyzed by nucleotide sequencing us-
ing an automated sequencer (ABI). Nucleotide and pre-
dicted amino acid sequences were compared with known
protein sequences deposited in GenBank by BLAST anal-
ysis.
Mammalian two-hybrid analysis
Full-length PTX1 was cloned in-frame with the Gal4
DNA-binding domain under the control of SV40 promoter
(Gal4-PTX1). A hybrid polypeptide containing the transac-
tivation domain of herpesvirus VP16 fused to NS5A was
also constructed (VP16-5A) using the mammalian expres-
sion vector VPFlag7 (Ghosh et al., 2000a). HepG2 cells
(with no evidence of hepatitis B virus genome, procured
from ATCC) were cotransfected with 1.0 g Gal4 respon-
sive reporter gene (gE1b-CAT), 1.0 g VP16-5A, and vary-
ing concentrations of Gal4-PTX1 effector plasmids. CAT
assay was performed 48 h posttransfection as previously
described (Ghosh et al., 2000a). In all the transfection ex-
periments, -galactosidase gene was included to normalize
the transfection efficiency.
Co-immunoprecipitation
HepG2 cells grown in 35-mm plates were transfected
with 1 g each of the CMV-NS5A and CMVFlag-PTX1
(human PTX1 cDNA with N-terminal Flag epitope cloned
under the control of CMV promoter) using lipofectamine
transfection system (Life Technologies, Inc). Cell lysates
were prepared 48 h posttransfection in 0.3 ml of low-
stringency lysis buffer (150 mM NaCl, 10 mM HEPES, pH
7.6, 0.1% Nonidet P-40, 5 mM EDTA) containing protease
inhibitors (2 g/ml aprotinin, 2 g/ml leupeptin, 1 g/ml
pepstatin, and 1 mM phenylmethylsulfonylfluoride). Each
cell lysate was incubated with Flag monoclonal antibody
and immobilized onto Protein A–Sepharose CL-4B beads
(Pharmacia). Immunoprecipitates were subjected to SDS–
PAGE, followed by Western blot analysis using either
NS5A or Flag-specific antibody.
Immunofluorescence study
HepG2 cells grown on glass coverslips were transfected
with NS5A and/or CMVFlag-PTX1 using lipofectamine.
Cells were washed 48 h posttransfection and fixed with
3.7% formaldehyde in PBS for 30 min. Cells were perme-
abilized with 0.2% Triton X-100 in PBS for 5 min, washed,
and incubated with either anti-NS5A rabbit polyclonal or
anti-Flag mouse monoclonal antibody for 1 h at room tem-
perature. Cells were washed and incubated with fluoro-
chrome-conjugated secondary antibodies for 30 min at room
temperature. Finally, cells were washed and mounted for
confocal microscopy (Bio-Rad 1024). Fluorescent images
were superimposed digitally to allow fine comparison. Co-
localization of green (FITC) and red (TRITC) signals in a
single pixel produces a yellow color, while separated signals
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remain green or red. Cells did not display a detectable
staining when negative control sera were used.
In vitro reporter gene assay
HepG2 cells were cotransfected with the human IFNA4-
luc reporter gene (Lin et al., 2000b) and/or CMV NS5A
with or without CMVFlag-PTX1 plasmid DNA using lipo-
fectamine. After 16 h of transfection, cells were either
infected with NDV (m.o.i. 5) or left uninfected. Luciferase
assay was performed 20-24 h postinfection as previously
described (Ghosh et al., 2000a).
Western blot for MxA
MxA was analyzed by Western blot as described earlier
(Schuster et al., 1996). Briefly, transfected HepG2 cells
were induced with NDV for 24 h prior to lysis by SDS–
PAGE buffer. Cell lysates were resolved on a SDS–8%
polyacrylamide gel, transferred to nitrocellulose membrane,
probed with a mouse monoclonal antibody to MxA, and
detected by chemiluminescence (ECL, Amersham).
Acknowledgments
We thank T. Morrison for providing NDV, P. Pitha and
R. Lin for IFN-reporter constructs, C.M. Rice for rabbit
polyclonal antibody to NS5A, S. Schneider-Schaulies for
monoclonal antibody to MxA, and F. Newman for propa-
gation of NDV. We are grateful to G.C. Sen and P. Pitha for
helpful discussion. This research was supported by PHS
Grant AI45144 from the National Institutes of Health.
References
Alter, H.J., Seeff, L.B., 2000. Recovery, persistence, and sequelae in
hepatitis C virus infection: a perspective on long-term outcome. Semin.
Liver Dis. 20, 17–35.
Au, W.C., Moore, P.A., LaFleur, D.W., Tombal, B., Pitha, P.M., 1998.
Characterization of the interferon regulatory factor-7 and its potential
role in the transcription activation of interferon A genes. J. Biol. Chem.
273, 29210–29217.
Bartenschlager, R., 2002. In vitro models for hepatitis C. Virus Res. 82,
25–32.
Bazzigher, L., Pavlovic, J., Haller, O., Staeheli, P., 1992. Mx genes show
weaker primary response to virus than other interferon-regulated genes.
Virology 186, 154–160.
Bigger, C.B., Brasky, K.M., Lanford, R.E., 2001. DNA microarray analysis
of chimpanzee liver during acute resolving hepatitis C virus infection.
J. Virol. 75, 7059–7066.
Blight, K.J., Kolykhalov, A.A., Rice, C.M., 2000. Efficient initiation of
HCV RNA replication in cell culture. Science 290, 1972–1974.
Castelruiz, Y., Larrea, E., Boya, P., Civeira, M.P., Prieto, J., 1999. Inter-
feron alfa subtypes and levels of type I interferons in the liver and
peripheral mononuclear cells in patients with chronic hepatitis C and
controls. Hepatology 29, 1900–1904.
Castet, V., Fournier, C., Soulier, A., Brillet, R., Coste, J., Larrey, D.,
Dhumeaux, D., Maurel, P., Pawlotsky, J.M., 2002. Alpha interferon
inhibits hepatitis C virus replication in primary human hepatocytes
infected in vitro. J Virol. 76, 8189–8199.
Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W., Hough-
ton, M., 1989. Isolation of a cDNA clone derived from a blood-borne
non-A, non-B viral hepatitis genome. Science 244, 359–362.
Chung, R.T., He, W., Saquib, A., Contreras, A.M., Xavier, R.J., Chawla,
A., Wang, T.C., Schmidt, E.V., 2001. Hepatitis C virus replication is
directly inhibited by IFN-alpha in a full-length binary expression sys-
tem. Proc. Natl. Acad. Sci. USA 98, 9847–9852.
Delhase, M., Castrillo, J.L., de la Hoya, M., Rajas, F., Hooghe-Peters, E.L.,
1996. AP-1 and Oct-1 transcription factors down-regulate the expres-
sion of the human PIT1/GHF1 gene. J. Biol. Chem. 271, 32349–32358.
DiBisceglie, A.M., 1997. Hepatitis C and hepatocellular carcinoma. Hepa-
tology 26, S34–S38.
Enomoto, N., Sakuma, I., Asahina, Y., Kurosaki, M., Murakami, T.,
Yamamoto, C., Izumi, N., Marumo, F., Sato, C., 1995. Comparison of
full-length sequences of interferon-sensitive and resistant hepatitis C
virus 1b. Sensitivity to interferon is conferred by amino acid substitu-
tions in the NS5A region. J. Clin. Invest. 96, 224–230.
Enomoto, N., Sakuma, I., Asahina, Y., Kurosaki, M., Murakami, T.,
Yamamoto, C., Ogura, Y., Izumi, N., Marumo, F., Sato, C., 1996.
Mutations in the nonstructural protein 5A gene and response to inter-
feron in patients with chronic hepatitis C virus 1b infection. N. Engl.
J. Med. 334, 77–81.
Fredericksen, B., Akkaraju, G. R., Foy, E., Wang, C., Pflugheber, J., Chen,
Z. J., Gale, M., Jr., 2002. Activation of the interferon-beta promoter
during hepatitis C virus RNA replication. Viral Immunol. 15, 29–40.
Gale, M., Jr., Kwieciszewski, B., Dossett, M., Nakao, H., Katze, M. G.,
1999. Antiapoptotic and oncogenic potentials of hepatitis C virus are
linked to interferon resistance by viral repression of the PKR protein
kinase. J. Virol. 73, 6506–6516.
Ghosh, A.K., Majumder, M., Steele, R., Yaciuk, P., Chrivia, J., Ray, R.,
Ray, R.B., 2000a. Hepatitis C virus NS5A protein modulates transcrip-
tion through a novel cellular transcription factor SRCAP. J. Biol.
Chem. 275, 7184–7188.
Ghosh, A.K., Majumder, M., Steele, R., Meyer, K., Ray, R., Ray, R.B.,
2000b. Hepatitis C virus NS5A protein protects against TNF-alpha
mediated apoptotic cell death. Virus Res. 67, 173–178.
Ghosh, A.K., Steele, R., Meyer, K., Ray, R., Ray, R.B., 1999. Hepatitis C
virus NS5A protein modulates cell cycle regulatory genes and pro-
motes cell growth. J. Gen. Virol. 80, 1179–1183.
Grakoui, A., Wychowski, C., Lin, C., Feinstone, S.M., Rice, C.M., 1993.
Expression and identification of hepatitis C virus polyprotein cleavage
products. J. Virol. 67, 1385–1395.
Guo, J.T., Bichko, V.V., Seeger, C., 2001. Effect of alpha interferon on the
hepatitis C virus replicon. J. Virol. 75, 8516–8523.
Hayashi, J., Aoki, H., Arakawa, Y., Hino, O., 1999. Hepatitis C virus and
hepatocarcinogenesis. Intervirology 42, 205–210.
Hijikata, M., Kato, N., Ootsuyama, Y., Nakagawa, M., Shimotohno, K.,
1991. Gene mapping of the putative structural region of the hepatitis C
virus genome by in vitro processing analysis. Proc. Natl. Acad. Sci.
USA 88, 5547–5551.
Hoofnagle, J. H., Di Bisceglie, A. M., 1997. The treatment of chronic viral
hepatitis. N. Engl. J. Med. 336, 347–356.
the German Acute Hepatitis C Therapy Group, Jaeckel, E., Cornberg, M.,
Wedemeyer, H., Santantonio, T., Mayer, J., Zankel, M., Pastore, G.,
Dietrich, M., Trautwein, C., Manns, M.P., 2001. Treatment of acute
hepatitis C with interferon alfa-2b. N. Engl. J. Med. 345, 1452–1457.
Jakschies, D., Zachoval, R., Muller, R., Manns, M., Nolte, K. U., Hoch-
keppel, H. K., Horisberger, M. A., Deicher, H., Von Wussow, P., 1994.
Strong transient expression of the type I interferon-induced MxA pro-
tein in hepatitis A but not in acute hepatitis B and C. Hepatology 19,
857–865.
Jeffers, L., 2000. Hepatocellular carcinoma: an emerging problem with
hepatitis C. J. Natl. Med. Assoc. 92, 369–371.
58 A.K. Ghosh et al. / Virology 306 (2003) 51–59
Kaito, M., Watanabe, S., Tsukiyama-Kohara, K., Yamaguchi, K., Koba-
yashi, Y., Konishi, M., Yokoi, M., Ishida, S., Suzuki, S., Kohara, M.,
1994. Hepatitis C virus particle detected by immunoelectron micro-
scopic study. J. Gen. Virol. 75, 1755–1760.
Kaneko, T., Tanji, Y., Satoh, S., Hijikata, M., Asabe, S., Kimura, K.,
Shimotohno, K., 1994. Production of two phosphoproteins from the
NS5A region of the hepatitis C viral genome. Biochem. Biophys. Res.
Commun. 205, 320–326.
Kato, N., Yokosuka, O., Hosoda, K., Ito, Y., Ohto, M., Omata, M., 1993.
Quantification of hepatitis C virus by competitive reverse transcription-
polymerase chain reaction: increase of the virus in advanced liver
disease. Hepatology 18, 16–20.
Keskinen, P., Nyqvist, M., Sareneva, T., Pirhonen, J., Melen, K., Julkunen,
I., 1999. Impaired antiviral response in human hepatoma cells. Virol-
ogy 263, 364–375.
Koev, G., Duncan, R.F., Lai, M.M., 2002. Hepatitis C virus IRES-depen-
dent translation is insensitive to an eIF2alpha-independent mechanism
of inhibition by interferon in hepatocyte cell lines. Virology 297,
195–202.
Kolykhalov, A.A., Agapov, E.V., Blight, K.J., Mihalik, K., Feinstone,
S.M., Rice, C.M., 1997. Transmission of hepatitis C by intrahepatic
inoculation with transcribed RNA. Science 277, 570–574.
Lin, R., Mamane, Y., Hiscott, J., 2000a. Multiple regulatory domains
control IRF-7 activity in response to virus infection. J. Biol. Chem. 275,
34320–34327.
Lin, R., Genin, P., Mamane, Y., Hiscott, J., 2000b. Selective DNA binding
and association with the CREB binding protein coactivator contribute
to differential activation of alpha/beta interferon genes by interferon
regulatory factors 3 and 7. Mol. Cell. Biol. 20, 6342–6353.
Lopez, S., Island, M.L., Drouin, J., Bandu, M.T., Christeff, N., Darracq, N.,
Barbey, R., Doly, J., Thomas, D., Navarro, S., 2000. Repression of
virus-induced interferon A promoters by homeodomain transcription
factor Ptx1. Mol. Cell. Biol. 20, 7527–7540.
Majumder, M., Ghosh, A.K., Steele, R., Ray, R., Ray, R.B., 2001. Hepatitis
C virus NS5A physically associates with p53 and regulates p21/waf1
gene expression in a p53-dependent manner. J. Virol. 75, 1401–1407.
Majumder, M., Ghosh, A.K., Steele, R., Zhou, X.Y., Phillips, N.J., Ray, R.,
Ray, R.B., 2002. Hepatitis C virus NS5A protein impairs TNF-medi-
ated hepatic apoptosis, but not by an anti-FAS antibody, in transgenic
mice. Virology 294, 94–105.
Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman,
M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M., Albrecht,
J.K., 2001. Peginterferon alfa-2b plus ribavirin compared with inter-
feron alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:
a randomised trial. Lancet 358, 958–965.
McHutchison, J.G., Gordon, S.C., Schiff, E.R., Shiffman, M.L., Lee,
W.M., Rustgi, V.K., Goodman, Z.D., Ling, M.H., Cort, S., Albrecht,
J.K., 1998. Interferon alfa-2b alone or in combination with ribavirin as
initial treatment for chronic hepatitis C. Hepatitis Interventional Ther-
apy Group. N. Engl. J. Med. 339, 1485–1492.
Moradpour, D., Blum, H. E., 1999. Current and evolving therapies for
hepatitis C. Eur. J. Gastroenterol. Hepatol. 11, 1199–1202.
Nousbaum, J.B., Pol, S., Nalpas, B., Landais, P., Berthelot, P., Brechot, C.,
1995. Hepatitis C virus type 1b (II) infection in France and Italy.
Collaborative Study Group. Ann. Intern. Med. 122, 161–168.
Patzwahl, R., Meier, V., Ramadori, G., Mihm, S., 2001. Enhanced expres-
sion of interferon-regulated genes in the liver of patients with chronic
hepatitis C virus infection: detection by suppression-subtractive hybrid-
ization. J. Virol. 75, 1332–1338.
Polyak, S.J., McArdle, S., Liu, S.L., Sullivan, D.G., Chung, M., Hofgart-
ner, W.T., Carithers, R.L., Jr., McMahon, B.J., Mullins, J.I., Corey, L.,
Gretch, D.R., 1998. Evolution of hepatitis C virus quasispecies in
hypervariable region 1 and the putative interferon sensitivity-determin-
ing region during interferon therapy and natural infection. J. Virol. 72,
4288–4296.
Poulin, G., Turgeon, B., Drouin, J., 1997. NeuroD1/beta2 contributes to
cell-specific transcription of the proopiomelanocortin gene. Mol. Cell.
Biol. 17, 6673–6682.
Poynard, T., Leroy, V., Cohard, M., Thevenot, T., Mathurin, P., Opolon,
P., Zarski, J.P., 1996. Meta-analysis of interferon randomized trials in
the treatment of viral hepatitis C: effects of dose and duration. Hepa-
tology 24, 778–789.
Reed, K.E., Rice, C.M., 2000. Overview of hepatitis C virus genome
structure, polyprotein processing, and protein properties. Curr. Top.
Microbiol. Immunol. 242, 55–84.
Reed, K.E., Xu, J., Rice, C.M., 1997. Phosphorylation of the hepatitis C
virus NS5A protein in vitro and in vivo: properties of the NS5A-
associated kinase. J. Virol. 71, 7187–7197.
Rosen, H.R., Ribeiro, R.R., Weinberger, L., Wolf, S., Chung, M., Gretch,
D.R., Perelson, A.S., 2002. Early hepatitis C viral kinetics correlate
with long-term outcome in patients receiving high dose induction
followed by combination interferon and ribavirin therapy. J. Hepatol.
37, 124–130.
Saito, I., Miyamura, T., Ohbayashi, A., Harada, H., Katayama, T., Kikuchi,
S., Watanabe, Y., Koi, S., Onji, M., Ohta, Y., Choo, Q., Houghton, M.,
Kuo, G., 1990. Hepatitis C virus infection is associated with the
development of hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA
87, 6547–6549.
Schiappa, D.A., Mittal, C., Brown, J.A., Mika, B.P., 2002. Relationship of
hepatitis C genotype 1 NS5A sequence mutations to early phase viral
kinetics and interferon effectiveness. J. Infect. Dis. 185, 868–877.
Schuster, A., Johnston, I. C., Das, T., Banerjeem, A. K., Pavlovic, J., ter
Meulen, V., Schneider-Schaulies, S., 1996. Expression of the human
MxA protein is associated with hyperphosphorylation of VSV P protein
in human neural cells. Virology 220, 241–245.
Sen, G.C., 2001. Viruses and interferons. Annu. Rev. Microbiol. 55,
255–281.
Servant, M. J., ten Oever, B., LePage, C., Conti, L., Gessani, S., Julkunen,
I., Lin, R., Hiscott, J., 2001. Identification of distinct signaling path-
ways leading to the phosphorylation of interferon regulatory factor 3.
J. Biol. Chem. 27, 355–363.
Szeto, D.P., Ryan, A.K., O’Connell, S.M., Rosenfeld, M.G., 1996. P-OTX:
a PIT-1-interacting homeodomain factor expressed during anterior pi-
tuitary gland development. Proc. Natl. Acad. Sci. USA 93, 7706–7710.
Tan, S.L., Katze, M.G., 2001. How hepatitis C virus counteracts the
interferon response: the jury is still out on NS5A. Virology 284, 1–12.
Tanji, Y., Kaneko, T., Satoh, S., Shimotohno, K., 1995. Phosphorylation of
hepatitis C virus-encoded nonstructural protein NS5A. J. Virol. 69,
3980–3986.
Tremblay, J.J., Drouin, J., 1999. Egr-1 is a downstream effector of GnRH
and synergizes by direct interaction with Ptx1 and SF-1 to enhance
luteinizing hormone beta gene transcription. Mol. Cell. Biol. 19, 2567–
2576.
Tremblay, J.J., Marcil, A., Gauthier, Y., Drouin, J., 1999. Ptx1 regulates
SF-1 activity by an interaction that mimics the role of the ligand-
binding domain. EMBO J. 18, 3431–3441.
Tremblay, J.J., Goodyer, C.G., Drouin, J., 2000. Transcriptional properties
of Ptx1 and Ptx2 isoforms. Neuroendocrinology 71, 277–286.
Yanagi, M., Purcell, R.H., Emerson, S.U., Bukh, J., 1997. Transcripts from
a single full-length cDNA clone of hepatitis C virus are infectious when
directly transfected into the liver of a chimpanzee. Proc. Natl. Acad.
Sci. USA 94, 8738–8743.
59A.K. Ghosh et al. / Virology 306 (2003) 51–59
